Summary. Major histocompatibility complex-linked immune response genes are thought to influence susceptibility to induction of both human insulin-dependent diabetes and murine streptozotocin-induced diabetes. To clarify this relationship, we administered streptozotocin intravenously in two doses (120 and 240 mg/kg body weight) on days 0 and 14, and monitored blood glucose until day 100 in young adult male mice of differing background genome and/or H-2 complex. In addition, we examined the effect of allogeneic whole blood transfusion on subsequent susceptibility to diabetes. B10 recombinant mice possessing the k allele at the centromeric H-2-K and I-A loci were most susceptible to diabetes induction.
Multiple-dose streptozotocin (STZ) diabetes in mice is accompanied by lymphocytic infiltration of islets, hyperglycaemia and hypoinsulinaemia, similar to human Type 1 (insulin-dependent) diabetes [1] . Major histocompatibility complex (MHC)-linked immune response genes are thought to influence susceptibility to induction of human Type I diabetes [2, 3] .
Several studies have suggested that susceptibility of mice to multiple-dose STZ treatment is influenced by genes within the MHC [3] [4] [5] [6] [7] . Kiesel et al. [7] , using five daily intraperitoneal injections of 50mg/kg body weight of STZ, found significant differences in the development of diabetes in B10 recombinant mice, and suggested that genes coding for susceptibility may be located in the centromeric (left) region of the H-2 complex.
We have obtained similar data with inbred, as well as recombinant B10 mice, using a regimen of two doses of STZ (120 and 240 mg/kg body weight) administered intravenously, 2weeks apart. Furthermore, we have found that prior blood transfusion delays the onset of hyperglycaemia.
Methods
STZ (2-deoxymethyl-nitrosourea-glucopyranose) was a gift from the Upjohn, Kalamazoo, Michigan, USA. Mice were obtained from Jackson Laboratories, Bar Harbor, Maine, USA, with the exception of Balb/k mice which were a gift from Dr. D. Sachs (National Institutes of Health) and B10.AQR mice, a gift from Dr. C. David (Mayo Clinic, Rochester, Minnesota, USA). All mice used were young adult males, aged 6-12 weeks. Animals were housed in groups of five in metabolic cages and were fed standard laboratory chow and water ad libitum. The numbers of mice studied for each strain are listed in Table 1 .
STZ was given in two intravenous doses, spaced 14 days apart (120 and 240 mg/kg), in citrate buffered saline (pH 4.5) via the femoral vein, under light ether anaesthesia. Data collected from each mouse included random blood glucose determinations [8] before and after treatment, and subsequently thrice weekly for 100 days. For the purpose of this study, diabetes was defined as blood glucose> 14 mmol/l for more than 10 days.
Donors of blood were B10.D2, B10.A(2R) and B10.A male mice which had been exposed to a double dose of intravenous STZ 7-10 days prior to exsanguination, and which were mildly hyperglycaemic (blood glucose 6.7-11.1 retool/l). Recipient B10.BR mice received heparinized whole blood (0.2 ml) transfusions via the femoral vein, under light ether anaesthesia, on two or three occasions weekly, followed by two intravenous doses of STZ commenced 3-7 days after the last transfusion. Control animals received no transfusion but similar STZ treatments.
Statistical analyses"
Chi square analysis was used to assess significance of differences in incidence of diabetes between concurrently STZ-treated mice of the several strains listed in Table 1 . All comparisons were made with the highly susceptible B10.BR strain.
Results
H-2 k B10.BR mice were highly susceptible to diabetes induction, whereas H-2 b B10 mice were highly resistant (p< 0.01, days 50-60) and H-2 d Ba0.D2 mice were only partially susceptible (p< 0.05, days 50-60; Fig. 1 , a Stable random blood glucose > 14 mmol/1 over more than 10 days; b STZ given 120 mg/kg body weight intravenously on day 0, and 240 mg/kg intravenously on day 14; c C3H.HEJ animals given a third dose of STZ on day 30 (300 mg/kg intravenously); d p < 0.01, Z 2 analysis, compared to incidence of diabetes in B10.BR mice; e p< 0.05, Z 2 analysis, compared to incidence of diabetes in B10.BR mice Table 1 ). In fact, 15% of B10.BR mice became diabetic after the first dose of STZ. At the K and I-A loci, k alleles conferred susceptibility, since B10.A(4R) mice were as susceptible to diabetes induction as were BI0.BR mice. Susceptibility of B10.MBR and B10.AQR mice, which like B10.BR and B10.A(4R), are kat the I-A locus, and the resistance of B10.A(5R) mice, which are b at the I-A locus, suggested that the I-A k genome may promote diabetes susceptibility in BI0 recombinant mice. Delay in onset of hyperglycaemia in B10.A(2R) was similar to that observed in relatively resistent BI0.D2 mice. This observation, as well as resistance of B10.(A) mice, suggests that I-A k susceptibility may be modulated by I-E, C or D alleles. Variation in susceptibility of different inbred strains with the same MHC genotype (i. e. C3H.HEJ, Balb/k and B10.BR) suggests that non-MHC genes also influence diabetes susceptibility in this model.
Transfusion of blood from STZ-exposed B10.D2 or B10.A(2R) donors prevented diabetes occurrence after the first intravenous dose of STZ, and delayed onset of hyperglycaemia in comparison with control animals (p < 0.01). Incidence of lasting diabetes following transfusion from B10.D2 and B10.A donors was similar to that of control animals ( Table 1) . Numbers of experimental versus control animals were too small to demonstrate postulated protection from diabetes in transfused mice.
Discussion
Our data support the hypothesis that immune response genes within the MHC modulate development of diabetes in B10 recombinant mice following intravenous exposure to STZ. MHC restriction of diabetes susceptibility in this model is the most persuasive evidence to date that it resembles human Type 1 diabetes.
Our method of STZ administration differs from that used in other studies. The findings confirm MHC, as well as non-MHC, influences upon susceptibility to intravenous STZ given in substantial doses spaced 2 weeks apart. Similarities between our data and those from other laboratories using different regimens suggest that the findings are generally valid.
Of particular interest is localization of STZ-diabetes susceptibility genes to the centromeric (left) side of the MHC. Our data are consistent with that of Kiesel et al. [7] , namely that k alleles at H-2-K and I-A loci are associated with susceptibility to STZ in B10 recombinant mice. Sensitivity of B10.MBR and B10.AQR mice, and resistance of B10.A(5R) mice further localize susceptibility to the I-A region. Immune response gene influences upon STZ-diabetes susceptibility correlate with similar I-A locus influences on susceptibility to murine autoimmune thyroiditis [9] , myasthenia gravis [10] and experimental allergic encephalitis [11] . Modulation of I-A region influences by other loci within the MHC are apparent in our experiments, and are consistent with recent evidence in studies of genetic regulation of the immune response to hepatitis-B surface antigen [12] , in which I-C sub-region genes were found to modulate I-A region susceptibility genes.
22.
In addition to MHC influences, our studies of different inbred strains of mice with the same MHC phenotype suggest that non-MHC genes also influence diabetes susceptibility in this murine model. It is evident therefore, that multiple genes within and outside of the MHC influence development of diabetes following intravenous exposure to streptozotocin.
Allogeneic whole blood transfusion modulated the onset of diabetes in B10.BR mice. The mechanism of this transfusion effect is as yet unknown. Our data are similar to findings in the BB rat [13] and are consistent with the beneficial transfusion effects on human kidney transplant survival [14] , which also remain largely unexplained. Transfusion effects on diabetes susceptibility will require further study.
